Polyvalent bacteria capsule polysaccharide-protein conjugate combined vaccine

Polyvalent bacteria capsule polysaccharide-protein conjugate combined vaccine

  • CN 1,709,505 B
  • Filed: 07/13/2005
  • Issued: 06/16/2010
  • Est. Priority Date: 07/13/2005
  • Status: Active Grant
First Claim
Patent Images

1. polyvalent bacterial polysaccharide-protein conjugate combined vaccine preparation, it is characterized in that, the A group'"'"'s epidemic cerebrospinal meningitis Neisseria gonorrhoeae capsular polysaccharide-protein conjugates that contains effective dose, C group'"'"'s epidemic cerebrospinal meningitis Neisseria gonorrhoeae pod membrane capsular polysaccharide-protein conjugates, Y group'"'"'s epidemic cerebrospinal meningitis Neisseria gonorrhoeae capsular polysaccharide-protein conjugates, W135 group'"'"'s epidemic cerebrospinal meningitis Neisseria gonorrhoeae capsular polysaccharide-protein conjugates and b type hemophilus influenza capsular polysaccharide-protein conjugates, contain A group in the preparation of its per unit dosage, C group, the amount of Y group and W135 group meningitis cocci capsular polysaccharide and b type hemophilus influenza capsular polysaccharide is between 5-25 μ

  • g.

View all claims
    ×
    ×

    Thank you for your feedback

    ×
    ×